The Food and Drug Administration (FDA) has approved anti‐PD‐1 antibodies, nivolumab, and pembrolizumab, for treatment of solid tumors including advanced NSCLC.7, 8, 9 The China Food and Drug Administration (CFDA) has recently approved nivolumab for the treatment of advanced NSCLC that lacks epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) mutations. This evidence concerns the gene ALK and non-small cell lung carcinoma.